SEARCH

SEARCH BY CITATION

References

  • 1
    Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health. 2008; 11: 213-220.
  • 2
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
  • 3
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-712.
  • 4
    Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145.
  • 5
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
  • 6
    Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. Paper presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas.
  • 7
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
  • 8
    Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics. 2007; 25: 429-442.
  • 9
    Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007; 110: 489-498.
  • 10
    McKeage K, Lyseng-Williamson KA. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics. 2008; 26: 699-719.
  • 11
    Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007; 25: 625-633.
  • 12
    Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007; 25: 634-641.
  • 13
    Rothman KJGS. Modern Epidemiology, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
  • 14
    Phillips CV, LaPole LM. Quantifying errors without random sampling. BMC Med Res Methodol. 2003; 3: 9.
  • 15
    Surveillance Research Program. SEER*Stat Software. Bethesda, MD: National Cancer Institute; 2008.
  • 16
    Francis GD, Dimech M, Giles L, Hopkins A. Frequency and reliability of estrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol. 2007; 60: 1277-1283.
  • 17
    Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004; 291: 1972-1977.
  • 18
    Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004; 5: 63-69.
  • 19
    Taucher S, Rudas M, Mader RM, et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer. 2003; 98: 2547-2553.
  • 20
    Huang HJ, Neven P, Drijkoningen M, et al. Association between tumor characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol. 2005; 58: 611-616.
  • 21
    Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003; 95: 142-153.
  • 22
    Prati R, Apple SK, He J, Gornbein JA, Chang HR. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J. 2005; 11: 433-439.
  • 23
    Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005; 97: 1254-1261.
  • 24
    Annual Estimates of the Population by Five-Year Age Groups and Sex for the United States: April 1, 2000 to July 1, 2006 (NC-EST2006-01). Washington, DC: US Census Bureau, Population Division; 2007.
  • 25
    Barron J, Cziraky M. Human epidermal growth factor receptors 2 (HER2) testing and treatment patterns among newly diagnosed breast cancer patients. Paper presented at: American Society of Clinical Oncology Meeting; September 5-7, 2008; Washington, DC.
  • 26
    Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007; 7: 153.
  • 27
    Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31: adjuvant chemotherapy with or without trastuzumab (H) in patients with HER2-positive breast cancer. Paper presented at: American Society of Clinical Oncology Meeting; June 1-5, 2007; Chicago, Illinois.
  • 28
    Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction in NSABP B-31: a randomized trial of AC to paclitaxel versus AC to paclitaxel with trastuzumab in HER2-positive, lymph node-positive, operable breast cancer. Paper presented at: American Society of Clinical Oncology Meeting; June 1-5, 2007; Chicago, Illinois.
  • 29
    Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in lymph node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23: 7811-7819.
  • 30
    Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008; 26: 1231-1238.
  • 31
    Consumer Price Index. Series ID: CUSR000SAM. Washington, DC: US Department of Labor, Bureau of Labor Statistics; 2008.
  • 32
    Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007; 99: 14-23.
  • 33
    Lidgren M, Wilking N, Jonsson B, Rehnberg C. Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care. 2007; 23: 223-231.
  • 34
    Drolet M, Maunsell E, Mondor M, et al. Work absence after breast cancer diagnosis: a population-based study. CMAJ. 2005; 173: 765-771.
  • 35
    May 2007 National Occupational Employment and Wage Estimates. Washington, DC: US Department of Labor, Bureau of Labor Statistics; 2008.
  • 36
    Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML. Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst. 2008; 100: 1763-1770.
  • 37
    Taylor R, Davis P, Boyages J. Long-term survival of women with breast cancer in New South Wales. Eur J Cancer. 2003; 39: 215-222.
  • 38
    Louwman WJ, Klokman WJ, Coebergh JW. Excess mortality from breast cancer 20 years after diagnosis when life expectancy is normal. Br J Cancer. 2001; 84: 700-703.
  • 39
    Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117: e25-e146.
  • 40
    National Comprehensive Cancer Network (NCCN). Breast cancer screening and diagnosis guidelines. NCCN Clinical Practice Guidelines in Oncology v.2.2008. Fort Washington, PA: NCCN; 2008. Available at: http:/www.nccn.org/professionals/physician_gls/PDF/breast-screening.pdf.
  • 41
    CooperH, HedgesLV, ValentineJC, eds. The Handbook of Research Synthesis and Meta-Analysis. 2nd ed. New York, NY: Russell Sage Foundation; 2009.
  • 42
    Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008; 100: 888-897.
  • 43
    Erikson C, Salsberg E, Forte G, Bruinooge S, Goldstein M. Future supply and demand of oncologists: challenges to assuring access to oncology services. J Oncol Pract. 2007; 3: 79-86.
  • 44
    Slamon DJ, Eiremann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC -> TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 neu positive early breast cancer patients: BCIRG 006 study. Paper presented at: San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, Texas.
  • 45
    Ramsey SD. How should we value lives lost to cancer? J Natl Cancer Inst. 2008; 100: 1742-1743.
  • 46
    Bradley CJ, Oberst K, Schenk M. Absenteeism from work: the experience of employed breast and prostate cancer patients in the months following diagnosis. Psychooncology. 2006; 15: 739-747.
  • 47
    de Boer AG, Taskila T, Ojajarvi A, van Dijk FJ, Verbeek JH. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA. 2009; 301: 753-762.
  • 48
    Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008; 100: 1672-1694.
  • 49
    Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007; 99: 1152-1161.